$JNCE Jounce Therapeutics, Inc. Insider Trading

FREE EMAIL WATCHDOG

Get free email notifications about insider trading in Jounce Therapeutics, Inc..

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview


Overview of insider trading in Jounce Therapeutics, Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in Jounce Therapeutics, Inc. for free.

CIK Number: 0001640455
IRS Number: 454870634
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Trading Symbol: JNCE
Company Address: 780 MEMORIAL DRIVE CAMBRIDGE 02139
Phone number: 857-259-3840

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Market Capitalization: $140.99M
Prev close: $17.30
Average Daily Volume: 711,175
Days Low: $17.19
Year Low: $16.33
Year High: $18.50

Jounce Therapeutics, Inc. Latest Insider Transactions

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Jun 14 2021JNCEJounce Therapeutic ...Third Rock Ventures II, L.P.10% OwnerSellJ0.001,500,00004,447,8295.9 M to 4.4 M (-25.22 %)
Apr 16 2021JNCEJounce Therapeutic ...Higgons John DuncanDirectorSellS10.002002,0009,7139.9 K to 9.7 K (-2.02 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...Option ExerciseM4.028,30033,366203,885
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...Option ExerciseM4.02100402212,185
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...Option ExerciseM4.025,10020,502212,285
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...SellS10.098,30083,74793,585101.9 K to 93.6 K (-8.15 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...BuyM4.028,30033,366101,88593.6 K to 101.9 K (+8.87 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...SellS10.001001,00093,58593.7 K to 93.6 K (-0.11 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...BuyM4.0210040293,68593.6 K to 93.7 K (+0.11 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...SellS10.095,10051,45993,58598.7 K to 93.6 K (-5.17 %)
Mar 31 2021JNCEJounce Therapeutic ...Trehu ElizabethChief Medical Offic ...BuyM4.025,10020,50298,68593.6 K to 98.7 K (+5.45 %)
Mar 17 2021JNCEJounce Therapeutic ...Higgons John DuncanDirectorSellS12.802002,5609,91310.1 K to 9.9 K (-1.98 %)
Mar 15 2021JNCEJounce Therapeutic ...Third Rock Ventures II, L.P.10% OwnerSellJ0.001,250,00006,500,3497.8 M to 6.5 M (-16.13 %)
Feb 18 2021JNCEJounce Therapeutic ...Higgons John DuncanDirectorSellS11.782002,35610,11310.3 K to 10.1 K (-1.94 %)
Feb 12 2021JNCEJounce Therapeutic ...Salter-Cid LuisaDirectorOption ExerciseA12.3631,400388,10431,400

View all Jounce Therapeutics, Inc. insider transactions.